HomeCompareHYP vs ABBV

HYP vs ABBV: Dividend Comparison 2026

HYP yields 0.13% · ABBV yields 3.67%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $20.1K in total portfolio value
10 years
HYP
HYP
● Live price
0.13%
Share price
$24.54
Annual div
$0.03
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$19.9K
Annual income
$13.11
Full HYP calculator →
ABBV
AbbVie Inc.
● Live price
3.67%
Share price
$168.90
Annual div
$6.20
5Y div CAGR
8.9%
Payout ratio
58%
After 10 yrs · $10,000 · DRIP
Portfolio value
$39.9K
Annual income
$1,154.43
Full ABBV calculator →

Portfolio growth — HYP vs ABBV

📍 ABBV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodHYPABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, HYP + ABBV cover 4 of 12 monthsgood coverage

Jan
ABBV
Feb
Mar
Apr
ABBV
May
Jun
Jul
ABBV
Aug
Sep
Oct
ABBV
Nov
Dec
HYP pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

HYP
Annual income on $10K today (after 15% tax)
$11.05/yr
After 10yr DRIP, annual income (after tax)
$11.14/yr
ABBV
Annual income on $10K today (after 15% tax)
$312.02/yr
After 10yr DRIP, annual income (after tax)
$981.27/yr
At 15% tax rate, ABBV beats the other by $970.12/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of HYP + ABBV for your $10,000?

HYP: 50%ABBV: 50%
100% ABBV50/50100% HYP
Portfolio after 10yr
$29.9K
Annual income
$583.78/yr
Blended yield
1.95%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

HYP
No analyst data
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+51.7% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

HYP buys
0
ABBV buys
0
No recent congressional trades found for HYP or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricHYPABBV
Forward yield0.13%3.67%
Annual dividend / share$0.03$6.20
Payout ratio50%58%
1-year div growth0%4.7%
5-year div CAGR0%8.9%
Portfolio after 10y$19.9K$39.9K
Annual income after 10y$13.11$1,154.43
Total dividends collected$131.00$7.2K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: HYP vs ABBV ($10,000, DRIP)

YearHYP PortfolioHYP Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$10,713$13.00$11,520$399.75$807.00ABBV
2$11,476$13.02$13,261$450.98$1.8KABBV
3$12,292$13.03$15,255$508.41$3.0KABBV
4$13,166$13.05$17,536$572.74$4.4KABBV
5$14,100$13.06$20,145$644.78$6.0KABBV
6$15,101$13.07$23,126$725.38$8.0KABBV
7$16,171$13.08$26,532$815.52$10.4KABBV
8$17,316$13.09$30,420$916.26$13.1KABBV
9$18,541$13.10$34,855$1,028.80$16.3KABBV
10$19,852$13.11$39,914$1,154.43$20.1KABBV

HYP vs ABBV: Complete Analysis 2026

HYPStock

An actively-managed ETF seeking capital appreciation. It invests at least 80% of its net assets in common stocks of “hypergrowth companies,” defined as those having a year-over-year sales growth rate of at least 40% in the most recently reported fiscal quarter. The adviser may include companies likely to become hypergrowth. Focus is primarily U.S.-listed stocks, but may include non-U.S. companies with U.S. listings or ADRs. The portfolio is expected to hold ~60-80 securities, with monthly rebalancing.

Full HYP Calculator →

ABBVHealthcare

AbbVie is a pharmaceutical giant best known for Humira and newer blockbusters Skyrizi and Rinvoq. A Dividend Aristocrat with 52+ years of consecutive dividend increases. Strong free cash flow generation supports its above-average yield. The company's diversified pipeline reduces dependence on any single drug.

Full ABBV Calculator →
📬

Get this HYP vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

HYP vs SCHDHYP vs JEPIHYP vs OHYP vs KOHYP vs MAINHYP vs JNJHYP vs MRKHYP vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.